Table of Contents Author Guidelines Submit a Manuscript
Retracted

This article has been retracted as it was found to contain falsified data. Additionally, it was found that the same article was published in Ginekologia Polska (2012, 83, 2, 111-115).

The Scientific World Journal
Volume 2012 (2012), Article ID 202804, 5 pages
http://dx.doi.org/10.1100/2012/202804
Clinical Study

Increasing the Stimulation Dose of rFSH in Unexpected Poor Responders Is Not Associated with Better IVF Outcome

IVF Unit, Department of Obstetrics and Gynecology, Haydarpasa Training Hospital, Gulhane Military Medical Academy, Haydarpasa, 34668 Istanbul, Turkey

Received 11 October 2011; Accepted 14 December 2011

Academic Editor: Jose G. Cecatti

Copyright © 2012 Levent Tutuncu and Ozgur Dundar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Kyrou, E. M. Kolibianakis, C. A. Venetis, E. G. Papanikolaou, J. Bontis, and B. C. Tarlatzis, “How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis,” Fertility and Sterility, vol. 91, no. 3, pp. 749–766, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. B. Vollenhoven, T. Osianlis, and J. Catt, “Is there an ideal stimulation regimen for IVF for poor responders and does it change with age?” Journal of Assisted Reproduction and Genetics, vol. 25, no. 11-12, pp. 523–529, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. M. H. A. Van Hooff, “The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose?” Journal of Assisted Reproduction and Genetics, vol. 12, no. 4, pp. 233–235, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Lashen, W. Ledger, Bernal A. López, B. Evans, and D. Barlow, “Superovulation with a high gonadotrophin dose for in vitro fertilization: is it effective?” Journal of Assisted Reproduction and Genetics, vol. 15, no. 7, pp. 438–443, 1998. View at Google Scholar
  5. L. Rombauts, “Is there a recommended maximum starting dose of FSH in IVF?” Journal of Assisted Reproduction and Genetics, vol. 24, no. 8, pp. 343–349, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. N. Lekamge, M. Lane, R. B. Gilchrist, and K. P. Tremellen, “Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve,” Journal of Assisted Reproduction and Genetics, vol. 25, no. 11-12, pp. 515–521, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. L. Pal, S. Jindal, B. R. Witt, and N. Santoro, “Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization,” Fertility and Sterility, vol. 89, no. 6, pp. 1694–1701, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. E. R. Klinkert, F. J. M. Broekmans, C. W. N. Looman, and E. R. Te Velde, “A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cycles,” Fertility and Sterility, vol. 81, no. 5, pp. 1247–1253, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. B. Popovic-Todorovic, A. Loft, S. Ziebe, and A. Nyboe Andersen, “Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in “standard” patients treated with 150 IU/day during the first cycle,” Acta Obstetricia et Gynecologica Scandinavica, vol. 83, no. 9, pp. 842–849, 2004. View at Publisher · View at Google Scholar · View at PubMed
  10. A. P. Ferraretti, A. La Marca, B. C. J. M. Fauser, B. Tarlatzis, G. Nargund, and L. Gianaroli, “ESHRE consensus on the definition of “poor response” to ovarian stimulation for in vitro fertilization: the Bologna criteria,” Human Reproduction, vol. 26, no. 7, pp. 1616–1624, 2011. View at Publisher · View at Google Scholar · View at PubMed
  11. N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser, “The science behind 25 years of ovarian stimulation for in vitro fertilization,” Endocrine Reviews, vol. 27, no. 2, pp. 170–207, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. G. E. Hofmann, J. P. Toner, S. J. Muasher, and G. S. Jones, “High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization,” Journal of In Vitro Fertilization and Embryo Transfer, vol. 6, no. 5, pp. 285–289, 1989. View at Google Scholar · View at Scopus
  13. V. C. Karande, G. S. Jones, L. L. Veeck, and S. J. Muasher, “High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients,” Fertility and Sterility, vol. 53, no. 3, pp. 486–489, 1990. View at Google Scholar · View at Scopus
  14. J. A. Land, M. I. Yarmolinskaya, J. C. M. Dumoulin, and J. L. H. Evers, “High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome,” Fertility and Sterility, vol. 65, no. 5, pp. 961–965, 1996. View at Google Scholar · View at Scopus
  15. C. Pantos, S. J. Thornton, A. L. Speirs, and I. Johnston, “Increasing the human menopausal gonadotropin dose - does the response really improve?” Fertility and Sterility, vol. 53, no. 3, pp. 436–439, 1990. View at Google Scholar · View at Scopus
  16. J. A. Garcia-Velasco, V. Isaza, A. Requena et al., “High doses of gonadotrophins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: a prospective, randomized, controlled trial,” Human Reproduction, vol. 15, no. 11, pp. 2292–2296, 2000. View at Google Scholar · View at Scopus
  17. H. J. Out, S. Lindenberg, A. L. Mikkelsen et al., “A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon(TM)) in women undergoing ovarian stimulation,” Human Reproduction, vol. 14, no. 3, pp. 622–627, 1999. View at Google Scholar · View at Scopus
  18. H. J. Out, I. David, R. Ron-El et al., “A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles,” Human Reproduction, vol. 16, no. 6, pp. 1104–1109, 2001. View at Google Scholar · View at Scopus
  19. H. J. Out, D. D. M. Braat, B. M. E. Lintsen, T. Gurkan, O. Bukulmez, O. Gokmen et al., “Increasing the daily dose of recombinant follicle stimulating hormone (puregon) does not compensate for age-related decline in retrievable oocytes after controlled ovarian hyperstimulation,” Human Reproduction, vol. 15, pp. 29–35, 2000. View at Google Scholar
  20. H. J. Out, “A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization,” Fertility and Sterility, vol. 76, no. 5, pp. 950–956, 2001. View at Publisher · View at Google Scholar
  21. B. C. Tarlatzis, L. Zepiridis, G. Grimbizis, and J. Bontis, “Clinical management of low ovarian response to stimulation for IVF: a systematic review,” Human Reproduction Update, vol. 9, no. 1, pp. 61–76, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. E. R. Klinkert, F. J. M. Broekmans, C. W. N. Looman, J. D. F. Habbema, and E. R. te Velde, “Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial,” Human Reproduction, vol. 20, no. 3, pp. 611–615, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. C. S. Siristatidis and M. P. Hamilton, “What should be the maximum FSH dose in IVF/ICSI in poor responders?” Journal of Obstetrics and Gynaecology, vol. 27, no. 4, pp. 401–405, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. M. D. Sterrenburg, S. M. Veltman-Verhulst, M. J.C. Eijkemans et al., “Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis,” Human Reproduction Update, vol. 17, no. 2, pp. 184–196, 2011. View at Publisher · View at Google Scholar · View at PubMed
  25. M. F. G. Verberg, N. S. Macklon, G. Nargund et al., “Mild ovarian stimulation for IVF,” Human Reproduction Update, vol. 15, no. 1, pp. 13–29, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. Fernández-Shaw, N. Pérez Esturo, R. Cercas Duque, and I. Pons Mallol, “Mild IVF using GnRH agonist long protocol is possible: comparing stimulations with 100 IU vs. 150 IU recombinant FSH as starting dose,” Journal of Assisted Reproduction and Genetics, vol. 26, no. 2-3, pp. 75–82, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. B. C. J. M. Fauser, G. Nargund, A. N. Andersen et al., “Mild ovarian stimulation for IVF: 10 years later,” Human Reproduction, vol. 25, no. 11, pp. 2678–2684, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. M. F. G. Verberg, M. J. C. Eijkemans, N. S. Macklon et al., “The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis,” Human Reproduction Update, vol. 15, no. 1, pp. 5–12, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus